Skip navigation
Agenda

Using Genome-Editing to Reduce Drug Development Timelines, Improve Clinical Outcomes and Optimize Manufacturing Processes

December 13, 2017
  • Cambridge, MA

Agenda

Want more agenda details? Download the brochure.

Wednesday, December 13, 2017

7:30

Main Conference Registration

8:30

Chairman’s Welcome and Opening Remarks

Jonathan Schmid-Burgk, PhD
Zhang Lab Postdoctoral Fellow
Broad Institute of MIT and Harvard

8:45

Mitigation of CRISPR Off-Target Effects Using Novel HiFi Cas9 Mutants

Mark A. Behlke, MD, PhD
Chief Scientific Officer
Integrated DNA Technologies, Inc.

9:30

Advance Research Using CRISPR and NGS

Michael G. Smith, PhD
Senior Sequencing Specialist
Illumina

10:15

Networking and Refreshment Break

10:45

Software Solutions for High — Throughput Genome Editing

Jonathan Schmid-Burgk, PhD
Zhang Lab Postdoctoral Fellow
Broad Institute of MIT and Harvard

11:30

Transform Genome-Editing Through A.I. Implementation

Niven Narain
Co-Founder, President & CEO
Berg Health

12:15

LUNCH AND LEARN | Fuel the Future

Meet your peers and exchange solutions across subject areas during a roundtable discussion on pressing issues related to CRISPR and explore future applications of the technology.

1:30

Use Novel Target Identification and Validation Techniques to Optimize Drug Discovery

Martin Akerman
CEO and co-founder
Envisagenics, Inc.

2:15

Building a Culture of Innovation

Amrit Chaudhuri
CEO & Founder
Mass Innovation Labs

3:00

Networking and Refreshment Break

3:30

Scaling Up the Promise of Genome-Editing

Lance Weed
Vice President, Operations
uniQure

4:15

Genome-Editing with CRISPR/Cas9 in Adoptive T-Cell Immunotherapies for Cancer

Marco Ruella, MD
Clinical Instructor, Associate Director,
Dr. June’s Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania

5:00

Close of Conference

Networking, Wine and Cheese Reception immediately following close of forum

Agenda

Want more agenda details? Download the brochure.
Want more agenda details? Download the brochure.

Wednesday, December 13, 2017

7:30

Main Conference Registration

8:30

Chairman’s Welcome and Opening Remarks

Jonathan Schmid-Burgk, PhD
Zhang Lab Postdoctoral Fellow
Broad Institute of MIT and Harvard

8:45

Mitigation of CRISPR Off-Target Effects Using Novel HiFi Cas9 Mutants

Mark A. Behlke, MD, PhD
Chief Scientific Officer
Integrated DNA Technologies, Inc.

9:30

Advance Research Using CRISPR and NGS

Michael G. Smith, PhD
Senior Sequencing Specialist
Illumina

10:15

Networking and Refreshment Break

10:45

Software Solutions for High — Throughput Genome Editing

Jonathan Schmid-Burgk, PhD
Zhang Lab Postdoctoral Fellow
Broad Institute of MIT and Harvard

11:30

Transform Genome-Editing Through A.I. Implementation

Niven Narain
Co-Founder, President & CEO
Berg Health

12:15

LUNCH AND LEARN | Fuel the Future

Meet your peers and exchange solutions across subject areas during a roundtable discussion on pressing issues related to CRISPR and explore future applications of the technology.

1:30

Use Novel Target Identification and Validation Techniques to Optimize Drug Discovery

Martin Akerman
CEO and co-founder
Envisagenics, Inc.

2:15

Building a Culture of Innovation

Amrit Chaudhuri
CEO & Founder
Mass Innovation Labs

3:00

Networking and Refreshment Break

3:30

Scaling Up the Promise of Genome-Editing

Lance Weed
Vice President, Operations
uniQure

4:15

Genome-Editing with CRISPR/Cas9 in Adoptive T-Cell Immunotherapies for Cancer

Marco Ruella, MD
Clinical Instructor, Associate Director,
Dr. June’s Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania

5:00

Close of Conference

Networking, Wine and Cheese Reception immediately following close of forum